Fixed-Dose Combinations for HIV/AIDS, Tuberculosis, and Malaria - Report of a Meeting Held 16-18 December 2003 Geneva
(2003; 199 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoSummary: Observations and some ways forward
Abrir esta carpeta y ver su contenidoWelcome
Abrir esta carpeta y ver su contenidoFixed-dose combinations for tuberculosis: lessons learned from a clinical, formulation and regulatory perspective
Abrir esta carpeta y ver su contenidoProduct costs of fixed-dose combination tablets in comparison with separate dispensing and or co-blistering of antituberculosis drugs
Abrir esta carpeta y ver su contenidoFixed-dose combinations: artemisinin-based combination therapies for malaria treatment
Abrir esta carpeta y ver su contenidoDeveloping combinations of drugs for malaria examination of critical issues and lessons learnt
Abrir esta carpeta y ver su contenidoSafety and long-term effectiveness of generic fixed-dose formulations of nevirapine-based HAART amongst antiretroviral-naïve HIV-infected patients in India
Cerrar esta carpetaEffect of introduction of fixed-dose combinations on the drug supply chain: experiences from the field
Ver el documentoAbstract
Ver el documentoIntroduction
Ver el documentoProcurement
Ver el documentoDistribution
Ver el documentoPrescribing
Ver el documentoDispensing to patients
Ver el documentoCost to patient
Ver el documentoPatient use
Ver el documentoConsumption data
Ver el documentoConclusion
Ver el documentoReferences
Abrir esta carpeta y ver su contenidoEffect of fixed-dose combination (FDC) medications on adherence and treatment outcomes
Abrir esta carpeta y ver su contenidoEffect of fixed-dose combination (FDC) drugs on development of clinical antimicrobial resistance: a review paper
Abrir esta carpeta y ver su contenidoFixed-dose combination (FDC) drugs availability and use as a global public health necessity: intellectual property and other legal issues
Abrir esta carpeta y ver su contenidoPharmaceutical development and quality assurance of FDCs
Ver el documentoAnnotated agenda
Ver el documentoList of participants
 

Consumption data

Health facilities are required to send information on drug consumption to the supply unit for use in quantifying drug needs. In case of ARVs this may also include patient code, drug combinations and quantities dispensed to each patient. If adequate inventory and requisition records are kept, or where the facilities and patients are few, it is easy to analyse the data and establish useful trends in the use of the drugs. However, when the numbers increase substantially, extracting individual drugs from the return forms becomes a challenge, especially since the individual drugs are distributed separately.

In some situations, data overload may lead to analyses being abandoned, especially in the absence of appropriate computer packages and trained personnel. The introduction of FDCs will make the gathering and analysis of consumption data easier.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013